Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive …

Oct 27, 2024 · Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating; Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating. TipRanks. Oct. …

CouponFollow Extension

18%
OFF

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong ...

1 week from now

Oct 25, 2024 · Total Revenue: $378.1 million for Q3 2024. Proprietary Product Portfolio Growth: 18% year-over-year. Vivitrol Net Sales: $113.7 million, 14% year-over-year growth. Aristada …

yahoo.com

18%
OFF

Alkermes' Q3 Proprietary Sales Soar 18% | The Motley Fool

1 week from now

Oct 24, 2024 · Revenue declined by 0.7% year over year to $378.1 million. Proprietary net sales grew by 18% to $273.0 million. GAAP net income from continuing operations increased 1.3% …

fool.com

7%
OFF

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have To Say

1 week from now

Oct 24, 2024 · Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same …

nasdaq.com

30%
OFF

Alkermes Jumped 30% In 3 Months; Big Profits - Investor's …

1 week from now

Oct 14, 2024 · Over the past four quarters Alkermes reported 277% earnings growth, then 20%, 155% and an 8% drop last quarter. Its EPS dip last quarter is partly due to a tough comp with …

investors.com

25%
OFF

Alkermes (ALKS) Q3 Earnings On The Horizon: Analysts' Insights

1 week from now

Oct 22, 2024 · In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.80 per share, reflecting an increase of 25% compared to the …

nasdaq.com

3%
OFF

Extendicare Inc (EXETF) Q3 2024 Earnings Call Highlights: Strong ...

1 week from now

1 day ago · Consolidated Q3 Revenue: Increased by 11.3% to $359.1 million. Adjusted EBITDA: Increased by $15.3 million or 73.8%. AFFO per Basic Share: Doubled to $0.28 from $0.14 in …

yahoo.com

89%
OFF

7 Analysts Assess Alkermes: What You Need To Know

1 week from now

May 2, 2024 · Revenue Growth: Alkermes's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 23.89% . …

businessinsider.com

7%
OFF

Strong Performance And Growth Potential For Axsome …

1 week from now

2 days ago · Goodman covers the Healthcare sector, focusing on stocks such as Alkermes, Biohaven Ltd., and Marinus. According to TipRanks , Goodman has an average return of 7.7% …

businessinsider.com

FAQs about Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive … Coupon?

Is Alkermes Plc a good stock to buy?

Positive Points Alkermes PLC (NASDAQ:ALKS) reported strong growth in its proprietary product portfolio, with net sales reaching $273 million, reflecting an 18% year-over-year increase. ...

How did Alkermes perform in Q1?

During the quarter, Alkermes saw strong organic growth in its proprietary product sales, which increased by 18% year-over-year. Vivitrol's revenue growth of 14% to $113.7 million was propelled by increased demand for alcohol-dependence treatments. Lybalvi performed exceptionally well, with a 47% revenue increase to $74.7 million. ...

Where is Alkermes plc headquartered?

Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland. ALKS | Complete Alkermes PLC stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

Should you buy Alkermes (Alkermes)?

Uy Ear has given his Buy rating due to a combination of factors that highlight Alkermes’ strong performance and future potential. The company’s third-quarter 2024 results were robust, primarily driven by the impressive performance of Vivitrol, which exceeded expectations. ...

Is Alkermes a good stock to buy in 2025?

Furthermore, Alkermes is poised to maintain its EBITDA above $200 million in 2025, despite an anticipated decline due to reduced royalty and manufacturing revenues. The management’s commitment to maintaining profitability and their strategic share repurchase plans further bolster confidence in the stock’s long-term value. ...

How did Alkermes perform in third-quarter 2024?

The company’s third-quarter 2024 results were robust, primarily driven by the impressive performance of Vivitrol, which exceeded expectations. Despite a slight miss in overall revenue primarily due to anticipated shifts in manufacturing revenues, Alkermes managed to surpass consensus forecasts for non-GAAP EPS. ...